|
Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
During 2020, the global pandemic pressured the FDA to focus on treatments, diagnostic tests, and prevention measures for SARS-CoV-2, the cause of COVID-19. However, the agency still approved 53 drugs as new molecular entities or new biologics – an increase over the 48 novel drugs approved in 2019.This issue summarizes key information on new, first-in-class medications for cholesterol management and two common skin conditions (acne vulgaris and actinic keratosis); the first drug for peanut allergy; the first oral gonadotropin-releasing hormone antagonist for prostate cancer; a new and improved pediculicide and ovicide for head lice; and a new catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease. A brief summary of 4 new oral therapies for non-small cell lung cancer (NSCLC) is also included. Usual dosing recommendations and drug interactions are provided in Table 1.Brief descriptions of 14 additional new drugs that may be commonly prescribed are provided in Table 2.
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.
The Rx Consultant is a publication of Continuing Education Network, Inc.
ACPE Universal Activity Number: 0428-0000-21-003-H01-P
Chief Editor and CE AdministratorTerry M. Baker, PharmD
Managing EditorTracy Farnen, PharmD
Associate EditorsJames Chan, PharmD, PhD Pharmacy Quality and Outcomes Coordinator Kaiser Permanente Oakland, CA
Associate Clinical Professor
Richard Ron Finley, B.S. Pharm.,R.Ph.
Consultant Pharmacist
Consult Pharmacist Aging and Adult Health Services
Julio R. Lopez, PharmD, FCSHP
Adjunct Clinical Professor |
Assistant Clinical Professor
Visiting Associate Professor and Lecturer Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Ambulatory Care Specialist - Diabetes
Senior Editorial AdvisorGerard Hatheway, PharmD, PhD
Editorial AdvisorsBelinda M. Danielson, RPh Christopher M. DeSoto, PharmD Angie S. Graham, PharmD Cynthia Chan Huang, PharmD, MBA Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse PractitionersEmily K. Meuleman, RN, C, MS |
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)